Scarica l'app Stockscreener
9.60
7.43%
-0.77
Dopo l'orario di chiusura:
9.50
-0.10
-1.04%
Olema Pharmaceuticals Inc Borsa (OLMA) Ultime notizie
Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential - Insider Monkey
Leading vs lagging indicators on Olema Pharmaceuticals Inc. performanceEarnings Summary Report & Breakout Confirmation Alerts - newser.com
How sustainable is Olema Pharmaceuticals Inc. stock dividend payoutSell Signal & High Return Stock Watch Alerts - newser.com
Can Olema Pharmaceuticals Inc. stock double in next 5 yearsPortfolio Risk Report & Risk Adjusted Buy/Sell Alerts - newser.com
Visual trend scoring systems applied to Olema Pharmaceuticals Inc.Portfolio Value Summary & Expert Approved Momentum Ideas - newser.com
Has Olema Pharmaceuticals Inc. found a price floorJuly 2025 Volume & Smart Investment Allocation Insights - newser.com
12 Best Hot Stocks to Invest In - Insider Monkey
Published on: 2025-10-13 10:23:49 - newser.com
Using flow based indicators on Olema Pharmaceuticals Inc.Earnings Recap Report & Technical Analysis for Trade Confirmation - newser.com
Institutional scanner results for Olema Pharmaceuticals Inc.July 2025 PostEarnings & AI Based Buy/Sell Signal Reports - newser.com
Why Olema Pharmaceuticals Inc. stock attracts global investorsWeekly Earnings Recap & Fast Exit/Entry Strategy Plans - newser.com
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 5.7%What's Next? - MarketBeat
Weiss Ratings Reiterates Sell (D-) Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Can momentum traders help lift Olema Pharmaceuticals Inc.2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Guggenheim Begins Coverage on Olema Pharmaceuticals (NASDAQ:OLMA) - Defense World
Does Olema Pharmaceuticals Inc. fit your quant trading modelEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Is now a turning point for Olema Pharmaceuticals Inc.2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com
Will Olema Pharmaceuticals Inc. benefit from macro trendsMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
Farther Finance Advisors LLC Grows Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - Defense World
Guggenheim Initiates Coverage on OLMA with a 'Buy' Rating and $2 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Guggenheim initiates coverage on Olema Pharmaceuticals stock with Buy rating - Investing.com
Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $24.00 - Defense World
What analysts say about Olema Pharmaceuticals Inc stockAnalyst Upgrades & Low Cost Portfolio Ideas - earlytimes.in
How moving averages guide Olema Pharmaceuticals Inc. tradingStop Loss & Stock Portfolio Risk Control - newser.com
How analysts rate Olema Pharmaceuticals Inc. stock todayEarnings Growth Report & Expert Verified Movement Alerts - newser.com
Will Olema Pharmaceuticals Inc. stock deliver better than expected guidanceQuarterly Profit Review & Step-by-Step Swing Trade Plans - newser.com
How to forecast Olema Pharmaceuticals Inc. trends using time seriesJuly 2025 Spike Watch & Weekly Chart Analysis and Trade Guides - newser.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Metastatic HR+/HER2− Breast Cancer Market Positioned For Accelerated Development Through 2034, Delveinsight Finds Novartis, Arvinas, Olema Pharma, Sichuan Baili Pharma, Ana C Garrido-Castro - Menafn.com
Metastatic HR+/HER2− Breast Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Arvinas, Olema Pharma, Sichuan Baili Pharma, Ana C Garrido-Castro - Barchart.com
Metastatic HR+/HER2 Breast Cancer Market Positioned - openPR.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Chart based exit strategy for Olema Pharmaceuticals Inc.Watch List & Stepwise Entry and Exit Trade Signals - newser.com
Cancer stocks rebound, outpacing broader markets in Q3 2025 - BioWorld MedTech
77,000-share award: Olema Pharmaceuticals grants stock options at $11.04 as inducement - Stock Titan
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 6.3%Time to Sell? - MarketBeat
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):